Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
第一作者:
Jørgen,Jahnsen
第一单位:
a 1 Akershus University Hospital, Lørenskog, Norway.;b 2 Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
作者:
主题词
青少年(Adolescent);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);消炎药(Anti-Inflammatory Agents);抗体, 单克隆(Antibodies, Monoclonal);结肠炎, 溃疡性(Colitis, Ulcerative);Crohn病(Crohn Disease);用药计划表(Drug Administration Schedule);女(雌)性(Female);胃肠病用药(Gastrointestinal Agents);人类(Humans);输注, 静脉内(Infusions, Intravenous);男(雄)性(Male);中年人(Middle Aged);挪威(Norway);前瞻性研究(Prospective Studies);缓解诱导(Remission Induction);疾病严重程度指数(Severity of Illness Index);时间因素(Time Factors);治疗结果(Treatment Outcome);肿瘤坏死因子α(Tumor Necrosis Factor-alpha);青年人(Young Adult)
DOI
10.1586/17474124.2015.1091308
PMID
26395534
发布时间
2022-04-10
- 浏览8
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文